Panbela Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-08-08: Study NCT05254171; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Recruiting.
- 2018-06-04: Study NCT03412799; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2016-01: Study NCT02657330; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-08-08 | NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Lead sponsor | Phase 2, Phase 3 | Recruiting | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV | 600 | 2027-01-01 |
| 2018-06-04 | NCT03412799 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Lead sponsor | Phase 1 | Completed | Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Stage IV Pancreatic Cancer | 50 | 2022-02-28 |
| 2016-01 | NCT02657330 Study of SBP-101 in Pancreatic Cancer | Lead sponsor | Phase 1 | Completed | Pancreatic Cancer; Ductal Adenocarcinoma of the Pancreas | 29 | 2017-10 |